Biopharmaceutical Market To Reach $816.30 Billion By 2033

December 2025 | Report Format: Electronic (PDF)

Biopharmaceutical Market Growth & Trends

The global biopharmaceutical market size is anticipated to reach USD 816.30 billion by 2033, growing at a CAGR of 6.55% from 2026 to 2033, according to a new report by Grand View Research, Inc. Key growth drivers include the rising prevalence of chronic diseases, increasing adoption of biologics for precision medicine, and advancements in biomanufacturing technologies. The growth is further supported by strong research and development investments, regulatory approvals for novel biologics, and expanding biosimilar adoption. The growing demand for monoclonal antibodies, cell and gene therapies, and recombinant proteins is reshaping treatment approaches across oncology, autoimmune diseases, and rare disorders.

The biopharmaceutical industry pipeline remains robust, with active research in gene therapies, RNA-based therapeutics, and bispecific antibodies targeting multiple indications. A notable breakthrough includes CRISPR-based gene editing therapies published in Nature Biotechnology in November 2024, demonstrating durable responses in sickle cell disease and beta-thalassemia patients.

In December 2024, Biogen and Samsung Bioepis secured EMA approval for their biosimilar adalimumab, expanding market competition in autoimmune disease treatment. This strategic move aligns with increasing global biosimilar adoption, addressing affordability challenges and improving access to high-quality biologics. With biosimilar penetration increasing across Europe and Asia, companies are leveraging cost-effective production strategies to enhance global market presence.

Additionally, the launch of subcutaneous biologics is transforming patient treatment experiences, offering convenient administration and reducing dependency on infusion centers. AbbVie’s subcutaneous formulation of infliximab, approved in February 2025, is expected to capture significant market share, improving adherence and patient satisfaction.

As part of industry advancements, Lonza participated as a Platinum Sponsor at the 2024 Biologics Manufacturing Conference held in Singapore from November 20–22, focusing on innovations in large-scale biologics production. The event highlighted biopharma manufacturing trends, including single-use bioreactors, process intensification, and AI-driven biologics development, shaping the next generation of high-efficacy therapies.

These strategic initiatives underscore the growing emphasis on biopharmaceutical innovation, market expansion, and regulatory advancements aimed at improving patient outcomes worldwide.

key Request a free sample copy or view report summary: Biopharmaceutical Market Report

Biopharmaceutical Market Report Highlights

The monoclonal antibody (mAb) segment led the market with the largest revenue share of 63.05% in 2025.
The oncology segment led the market with the largest revenue share of 31.17% in 2025.
The proprietary (Branded) biopharmaceuticals segment led the market with the largest revenue share of 77.45% in 2025.
The outsourced drug development segment led the market with the largest revenue share of 56.62% in 2025.
The injectable formulations (IV, IM, SC) segment led the market with the largest revenue share of 92.64% in 2025.
North America dominated the global biopharmaceutical market with the largest revenue share of 54.35% in 2025.

Biopharmaceutical Market Segmentation

Grand View Research has segmented the global biopharmaceutical market on the basis of molecule type, disease, drug type, drug development type, formulation, route of administration, prescription type, sales channel, and region:

Biopharmaceutical Molecule Type Outlook (Revenue, USD Million, 2021 - 2033)